{"filing":{"accession_number":"0001104659-26-111921","cik":"0001857190","ticker":"NYXH","company_name":"Nyxoah SA","form":"6-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"tm2626577d1_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1857190/000110465926111921/tm2626577d1_6k.htm"},"events":[{"id":35726,"run_id":32925,"accession_number":"0001104659-26-111921","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Nyxoah announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. This is a material executive appointment of a named officer to a principal leadership role. Kelly brings 25+ years of MedTech leadership experience, including prior service as Chairman, President and CEO of Teleflex, and his appointment reflects the company's strategic shift to a U.S.-focused commercial organization following FDA approval of its Genio product.","company_name":"Nyxoah SA","ticker":"NYXH","filing_date":"2026-09-29","form":"6-K","submitted_at":null,"items":[{"id":39887,"accession_number":"0001104659-26-111921","item_number":"EX-99.1","item_title":"tm2626577d1_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Nyxoah announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. This is a material executive appointment of a named officer to a principal leadership role. Kelly brings 25+ years of MedTech leadership experience, including prior service as Chairman, President and CEO of Teleflex, and his appointment reflects the company's strategic shift to a U.S.-focused commercial organization following FDA approval of its Genio product.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:05:46.920789+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39887,"accession_number":"0001104659-26-111921","item_number":"EX-99.1","item_title":"tm2626577d1_ex99-1.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Nyxoah announced the appointment of Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman. This is a material executive appointment of a named officer to a principal leadership role. Kelly brings 25+ years of MedTech leadership experience, including prior service as Chairman, President and CEO of Teleflex, and his appointment reflects the company's strategic shift to a U.S.-focused commercial organization following FDA approval of its Genio product.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:05:46.920789+00:00","company_name":"Nyxoah SA","ticker":"NYXH","filing_date":"2026-09-29"}]}